MX2021005416A - Combinación de quimioterapia con lectina de s. rolfsii recombinante. - Google Patents

Combinación de quimioterapia con lectina de s. rolfsii recombinante.

Info

Publication number
MX2021005416A
MX2021005416A MX2021005416A MX2021005416A MX2021005416A MX 2021005416 A MX2021005416 A MX 2021005416A MX 2021005416 A MX2021005416 A MX 2021005416A MX 2021005416 A MX2021005416 A MX 2021005416A MX 2021005416 A MX2021005416 A MX 2021005416A
Authority
MX
Mexico
Prior art keywords
combination
recombinant
chemotherapy
therapeutic agents
rolfsii lectin
Prior art date
Application number
MX2021005416A
Other languages
English (en)
Inventor
Dhananjay Sathe
Sudeep Kumar
Sachin Prabhakar Bachate
Mohanish Pradeep Kankonkar
Original Assignee
Unichem Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unichem Lab Ltd filed Critical Unichem Lab Ltd
Publication of MX2021005416A publication Critical patent/MX2021005416A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a la quimioterapia combinada con proteína lectina recombinante. La invención se refiere específicamente al efecto citotoxico de la proteína lectina recombinante que tiene la secuencia de aminoácidos de SEQ ID NO: 1 en combinación con otros agentes terapéuticos, en donde los otros agentes terapéuticos son agentes anticancerosos. Las combinaciones son altamente sinérgicas y eficaces contra varios canceres.
MX2021005416A 2018-11-19 2019-11-18 Combinación de quimioterapia con lectina de s. rolfsii recombinante. MX2021005416A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201821043455 2018-11-19
IN201821022667 2018-12-18
PCT/IB2019/059873 WO2020104911A1 (en) 2018-11-19 2019-11-18 Combination of chemotherapy with recombinant s. rolfsii lectin

Publications (1)

Publication Number Publication Date
MX2021005416A true MX2021005416A (es) 2021-07-06

Family

ID=68887075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005416A MX2021005416A (es) 2018-11-19 2019-11-18 Combinación de quimioterapia con lectina de s. rolfsii recombinante.

Country Status (12)

Country Link
US (1) US20220257704A1 (es)
EP (1) EP3883560A1 (es)
JP (1) JP2022508066A (es)
KR (1) KR20210093250A (es)
CN (1) CN113329772B (es)
AU (1) AU2019383003A1 (es)
BR (1) BR112021008961A2 (es)
CA (1) CA3118053A1 (es)
MX (1) MX2021005416A (es)
SG (1) SG11202104787PA (es)
WO (1) WO2020104911A1 (es)
ZA (1) ZA202102734B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020311050A1 (en) * 2019-07-09 2021-12-23 Unichem Laboratories Ltd Stable formulations of recombinant proteins
CA3227834A1 (en) * 2021-08-30 2023-03-09 Dhananjay Sathe Protein compositions for the treatment of inflammatory diseases
AU2022356491A1 (en) * 2021-10-01 2024-03-14 Unichem Laboratories Limited Recombinant glycan binding proteins and its use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053386A (en) 1987-07-24 1991-10-01 Tung Ta C Orally administrable anti-metastatic lectin compositions and methods
SI2430041T1 (sl) * 2009-02-18 2019-04-30 Unichen Laboratories Limited Unichem Bhavan, Prabhat Estate Rekombinantni lektini, ki vežejo rakaste celice, z antitumorskim delovanjem in postopek priprave
WO2014203261A2 (en) * 2010-02-02 2014-12-24 Unichem Laboratories Ltd. Recombinant lectin and method of preparing thereof
EP3429613A4 (en) * 2016-03-14 2020-01-15 Kiromic, Inc. COMPOSITIONS AND METHODS FOR TREATING CANCER

Also Published As

Publication number Publication date
BR112021008961A2 (pt) 2021-08-31
ZA202102734B (en) 2022-07-27
CN113329772A (zh) 2021-08-31
WO2020104911A1 (en) 2020-05-28
US20220257704A1 (en) 2022-08-18
CN113329772B (zh) 2023-07-18
SG11202104787PA (en) 2021-06-29
JP2022508066A (ja) 2022-01-19
AU2019383003A1 (en) 2021-06-03
CA3118053A1 (en) 2020-05-28
EP3883560A1 (en) 2021-09-29
KR20210093250A (ko) 2021-07-27

Similar Documents

Publication Publication Date Title
MX2021005416A (es) Combinación de quimioterapia con lectina de s. rolfsii recombinante.
MX2017011847A (es) Modulación de inmunidad tumoral por liberación de o2 mediada por proteína.
MX2022006511A (es) Polipeptidos efectores de la sub-unidad a de la toxina shiga, andamiajes de los efectores de la toxina shiga, y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
WO2020061194A3 (en) Compositions and methods for treating cancer with duocars
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
MX2021003475A (es) Metodos de purificacion de proteinas.
NZ761188A (en) Antibody molecules to tim-3 and uses thereof
BR112019008349A2 (pt) composição de peptídeos, e, utilização de uma composição.
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2016002937A (es) Vacuna oncologica.
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
PH12018500098A1 (en) Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
EP4011906A3 (en) Lactase enzymes with improved properties
MX2021002295A (es) Variantes de proteinas recombinantes.
MX2021006945A (es) Anelosomas para suministrar modalidades terapéuticas de reemplazo de proteínas.
MX2022011248A (es) Metodos y composiciones relacionados con nanoportadores sinteticos.
PH12021550122A1 (en) Solubilized apyrases, methods and use
NZ744289A (en) Composition containing amino acids
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
FR3001729B1 (fr) Mutants du facteur x
EA202190973A1 (ru) Комбинированная химиотерапия с рекомбинантным белком